Oxford BioMedica Annual General Meeting

RNS Number : 4651A
Oxford Biomedica PLC
07 June 2016
 

 

Oxford BioMedica Annual General Meeting

 

London, UK - 7 June 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

 

·      Resolution 9: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and

 

·      Resolution 10: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

 

Certified copies of the document setting out the above resolutions passed at the 2016 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

 

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (3 June 2016) there were 2,703,149,291 1p ordinary shares in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld

 

Total

votes cast

Result









Ordinary resolutions














1

1,485,649,973

3,312,033

2,846,516

38,490

33,512

1,491,880,524

Passed









2

1,476,569,089

3,441,302

2,846,516

1,251,449

7,772,168

1,491,880,524

Passed









3

1,485,481,782

3,315,455

2,846,516

74,890

145,180

1,491,863,823 

Passed

4

 

1,483,363,810

 

3,326,126

 

2,846,516

 

2,134,604

 

209,468

 

1,491,880,524

 

Passed









5

1,370,961,344

3,315,455

2,846,516

111,174,129

3,583,080

1,491,880,524

Passed









6

1,485,446,226

3,355,455

2,846,516

87,809

144,518

1,491,880,524

Passed









7

1,395,088,017

3,321,608

2,846,516

87,748,985

2,875,398

1,491,880,524

Passed









8

1,485,136,315

3,389,372

2,846,516

443,395

64,926

1,491,880,524

Passed

















 

Special resolutions














9

1,484,857,700

3,403,028

2,846,516

663,953

109,327

1,491,880,524

Passed









10

1,483,284,959

3,449,017

2,846,516

2,194,336

105,696

1,491,880,524

Passed









 

 

 

 

- Ends -

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGEAAKXEFDKEFF